A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE (RIFLE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03098823|
Recruitment Status : Active, not recruiting
First Posted : April 4, 2017
Last Update Posted : December 3, 2018
|Condition or disease||Intervention/treatment||Phase|
|Lupus Erythematosus, Systemic Lupus Erythematosus Fatigue||Drug: RAYOS Drug: Prednisone||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||62 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Randomized, Double-Blind, Active Comparator-Controlled, Crossover Study to Assess the Capacity of RAYOS® Compared to Immediate-Release Prednisone to Improve Fatigue and Control Morning Symptoms in Subjects With Systemic Lupus Erythematosus|
|Actual Study Start Date :||September 12, 2017|
|Estimated Primary Completion Date :||April 2019|
|Estimated Study Completion Date :||July 2019|
FDA approved RAYOS for indication of fatigue in Lupus.
|Active Comparator: IR prednisone||
FDA approved corticosteroid frequently used for SLE.
- Fatigue [ Time Frame: 3 months ]Fatigue as measured in FACIT-F by patient
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03098823